Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Revelation Biosciences selected Avance Clinical as the contract research organization for its Phase 2/3 adaptive-design TITAN study. The trial will evaluate the company's proprietary formulation, Gemini, as a treatment for patients with acute kidney injury.
Key figures
- Drug Name
- Gemini
- Phase Of Trial
- Phase 2/3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.